This article is more than 5 years old. Information may no longer be current.
IL-25 impacts pathogenesis of chronic rhinosinusitis in Asians
Interleukin-25 secretions generated from the sinonasal epithelia and infiltrating mast cells play a crucial role in the pathogenesis of chronic rhinosinusitis among Asian patients with nasal polyps, according to study results.
“IL-25 production by bronchial and nasal epithelial cells is regulated by transcription and protein expression, and allergen proteases can play pivotal roles in both of these biological processes,” Hyun-Woo Shin, MD, PhD, of the Seoul National University College of Medicine, and colleagues wrote. “Blocking IL-25 activity could be a novel therapeutic strategy to improve clinical outcomes of patients with nasal polyposis.”
The researchers collected sinonasal and polyp tissues from routine endoscopic sinus surgery in patients with chronic rhinosinusitis (CRS) to determine the role of IL-25. Control tissues were collected from patients without any sinonasal disease during other rhinologic surgeries such as orbital decompression surgery. Researchers also gathered uncinated process (UP) tissue from controls (n = 27) and patients with CRS, including those with nasal polyps (n = 50) and patients without polyps (n = 65).
An increase was observed in IL-25 inflammatory cell numbers in nasal polyps (n = 145.8) and UPs (150.9) of patients with polyps compared with those in UPs from control patients (89.5) and patients without polyps (149.3). The inflammatory markers included: T-box transcription factor, RAR-related orphan receptor C, GATA3, eosinophil cationic protein and TGF-beta.
“Regarding the cellular source of IL-25, we also observed that tryptase-positive cells were one of the abundant cell types among the infiltrating inflammatory IL-25+ cells in human [nasal polyp] tissues,” the researchers wrote. “Our results suggest the novel possibility of treating nasal polyposis with anti-IL-25 therapy.”
Disclosure: The researchers report no relevant financial disclosures.